Market Overview:
The Indian vaccine market size is expected to exhibit a growth rate (CAGR) of 12.3% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year |
2023 |
Forecast Years |
2024-2032 |
Historical Years |
2018-2023
|
Market Growth Rate 2024-2032
|
12.3% |
A vaccine is a biological substance that is developed to boost the immune system while protecting against bacterial and viral diseases. It comprises live attenuated, inactivated, toxoid, mRNA, viral vector, and subunit, recombinant, polysaccharide, and conjugate vaccines. It is consumed orally, by aerosol, or through injections to prevent several diseases, such as measles, polio, tetanus, influenza, rabies, and whooping cough. In addition, it stimulates the body to make antibodies against antigens or pathogens. At present, there is a rise in the production of vaccines in India due to technological advancements and the increasing number of cold chain storage facilities.
Indian Vaccine Market Trends:
The Government of India (GOI) is currently launching various campaigns, such as the Universal Immunization Program (UIP), to increase immunization coverage against vaccine-preventable diseases in the country. This, along with the growing health awareness among the masses, represents one of the key factors driving the market in India. Moreover, the rising export of generic medicines in India that imitates brand-name drugs in effect, strength, doses, qualities, forms, administration, and safety is contributing to the growth of the market. In addition, there is an increase in the number of private companies that are producing cost-effective vaccines and investing in their distribution throughout India. This, coupled with the burgeoning healthcare industry, is strengthening the growth of the market in the country. Besides this, key market players are extensively investing in research and development (R&D) activities to introduce new and enhanced vaccines. They are also focusing on developing innovative ways to distribute vaccines effectively within the country and international markets, which is catalyzing the demand for Indian vaccines. Other factors propelling the market growth are the increasing population, inflating income levels of individuals, improving existing vaccine infrastructure, the expanding logistics industry, and the growing participation of non-governmental organizations (NGOs).
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the Indian vaccine market report, along with forecasts for the period 2024-2032. Our report has categorized the market based on monovalent and combined vaccines.
Breakup by Monovalent and Combined Vaccines:
- BCG
- HIB
- Influenza
- Varicella
- Typhoid
- Japanese Encephalitis
- Measles
- Tetanus Toxoid
- Hepatitis A
- Rubella
- Diphtheria
- Tetanus, and Pertussis (DPT)
- Oral Polio Vaccine (OPV)
- MMR
- Rotavirus
- Hepatitis B
- Pneumococcal
- Meningococcal
- Rabies
- HPV
- Hexavalent
- Dengue vaccines
The Focus of the Analysis for Each Vaccine
- Vaccine Overview
- Historical and Current Market Trends
- Market Breakup by Prescriber
- Market Breakup by Public and Private Sector
- Market Outlook
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
Million, INR Million |
Scope of the Report
|
Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- Monovalent and Combined Vaccines
|
Monovalent and Combined Vaccines Covered |
BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue vaccines |
Companies Covered |
GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |